2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: ASN.2007060688v1 19/1/102    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, X. Articles by Torres, V. E. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Articles by Torres, V. E. Related Collections Related Articles

Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease

Mayo Clinic College of Medicine, Rochester, Minnesota

Correspondence: Dr. Vicente E. Torres, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: 507-284-7572; Fax: 507-266-9315; E-mail: torres.vicente{at}mayo.edu

Received for publication June 20, 2007. Accepted for publication August 2, 2007.

The polycystic kidney diseases (PKD) are a group of genetic disorders causing renal failure and death from infancy to adulthood. Arginine vasopressin (AVP) V2 receptor antagonists inhibit cystogenesis in animal models of cystic kidney diseases, presumably by downregulating cAMP signaling, cell proliferation, and chloride-driven fluid secretion. For confirmation that the protective effect of these drugs is due to antagonism of AVP, PCK (Pkhd1^–/–) and Brattleboro (AVP^–/–) rats were crossed to generate rats with PKD and varying amounts of AVP. At 10 and 20 weeks of age, PCK AVP^–/– rats had lower renal cAMP and almost complete inhibition of cystogenesis compared with PCK AVP^+/+ and PCK AVP^+/– rats. The V2 receptor agonist 1-deamino-8-d-arginine vasopressin increased renal cAMP and recovered the full cystic phenotype of PCK AVP^–/– rats and aggravated the cystic disease of PCK AVP^+/+ rats but did not induce cystic changes in wild-type rats. These observations indicate that AVP is a powerful modulator of cystogenesis and provide further support for clinical trials of V2 receptor antagonists in PKD.

Related Articles

This Month's Highlights
J. Am. Soc. Nephrol. 2008 19: A13. [Full Text] [PDF]

This article has been cited by other articles:

				G. Alonso, E. Galibert, V. Boulay, A. Guillou, A. Jean, V. Compan, and G. Guillon Sustained Elevated Levels of Circulating Vasopressin Selectively Stimulate the Proliferation of Kidney Tubular Cells via the Activation of V2 Receptors Endocrinology, January 1, 2009; 150(1): 239 - 250. [Abstract] [Full Text] [PDF]

				D. P. Wallace, M. T. Quante, G. A. Reif, E. Nivens, F. Ahmed, S. J. Hempson, G. Blanco, and T. Yamaguchi Periostin induces proliferation of human autosomal dominant polycystic kidney cells through {alpha}V-integrin receptor Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1463 - F1471. [Abstract] [Full Text] [PDF]

				V. E. Torres Role of Vasopressin Antagonists Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1212 - 1218. [Abstract] [Full Text] [PDF]

				J. P. Calvet Strategies to Inhibit Cyst Formation in ADPKD Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1205 - 1211. [Abstract] [Full Text] [PDF]

				J. J. Grantham Therapy for Polycystic Kidney Disease? It's Water, Stupid! J. Am. Soc. Nephrol., January 1, 2008; 19(1): 1 - 7. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673